Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence
In real-world, the risk of cardiovascular and renal complications rises as kidney function declines and albuminuria worsens. Guideline-recommended therapies remain underused.
Authors
- Manuel Gorostidi (ORCID: https://orcid.org/0000-0002-5226-1937)
- Roberto Alcázar Arroyo (ORCID: https://orcid.org/0000-0002-7433-3479)
- Unai Aranda
- Beatriz Palacios (ORCID: https://orcid.org/0009-0002-0089-2291)
- Rafael Santamaría (ORCID: https://orcid.org/0000-0002-2627-1445)
- Margarita Capel (ORCID: https://orcid.org/0000-0001-9431-6302)
- Ana Cebrián
- Ignacio Hernández
- Carlos Escobar (ORCID: https://orcid.org/0009-0003-7350-3098)
Institutions
- Hospital Universitario La Paz (ES)
- Universidad Politécnica de Cartagena (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Institute for Research in Biomedicine (ES)
- Madrid Health Service (ES)
- Hospital Universitario Central de Asturias (ES)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Hospital Universitario Infanta Leonor (ES)
- University of Córdoba (ES)
- Universidad de Murcia (ES)
Publication Details
- Journal
- Nefrología (English Edition)
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.nefroe.2025.501340
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00